中医药治疗再生障碍性贫血的研究进展*

doi:10.3969/j.issn.1671-2587.2024.05.023

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (5): 715-720.DOI: 10.3969/j.issn.1671-2587.2024.05.023

• 综述 • 上一篇

中医药治疗再生障碍性贫血的研究进展^*

蒲有为, 胡雪, 罗金莲, 余泽波

重庆医科大学附属第一医院输血科,重庆 400016

收稿日期:2024-06-29 出版日期:2024-10-20 发布日期:2024-09-20
通讯作者: 余泽波,主要从事用血管理及经血传播疾病方面研究,（E-mail）yuzebo2001@163.com。
作者简介:蒲有为,主要从事中西医结合输血研究,（E-mail）youweipu@hospital.cqmu.edu.cn。
基金资助:
*本课题受2023年重庆市输血协会华兰生物科研基金项目资助

Research Progress in Treatment of Aplastic Anemia with Traditional Chinese Medicine

PU Youwei, HU Xue, LUO Jinlian, YU Zebo

The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016

Received:2024-06-29 Online:2024-10-20 Published:2024-09-20

摘要/Abstract

摘要： 再生障碍性贫血 (aplastic anemia, AA)是一种骨髓造血衰竭性疾病。成分输血是AA患者改善贫血和维持生活质量的必要条件。然而长期输血易导致输血依赖性,且当前血液供应紧缺,满足AA患者的输血需求亦愈加困难。因此,对AA进行“患者血液管理”（patient blood management, PBM）,应用各种非输血方法改善贫血,减少异体血的输注,提高AA患者的生活质量尤为重要。中医药治疗可以改善AA患者的贫血症状,减少异体输血需求,有利于AA患者的血液管理。本文对治疗AA的中医药和作用机制进行了综述,并探讨中医药在AA患者血液管理中的临床意义。

关键词: 再生障碍性贫血, 患者血液管理, 中医药, 网络药理学

Abstract: Aplastic anemia (AA) is a bone marrow hematopoietic failure disease. Blood component transfusion is necessary to treat anemia and maintain quality of life in AA patients. However, long-term blood transfusion easily leads to transfusion dependence, and the current blood supply is insufficient, and it is also increasingly difficult to meet the blood transfusion needs of AA patients. Therefore, it is particularly important to perform "patient blood management" (PBM) for AA, apply various non-transfusion methods to treat anemia, reduce the transfusion of allogeneic blood, and improve the quality of life of AA patients. Traditional Chinese medicine (TCM) treatment can improve the symptoms of anemia in AA patients, reduce the need for allogeneic blood transfusion, and facilitate the blood management of AA patients. This article reviews the traditional Chinese medicine and its mechanism of action in the treatment of AA, and discusses the clinical significance of traditional Chinese medicine in the blood management of AA patients.

Key words: Aplastic Anemia, Patient Blood Management, Traditional Chinese Medicine, Network Pharmacology

中图分类号:

R457

蒲有为, 胡雪, 罗金莲, 余泽波. 中医药治疗再生障碍性贫血的研究进展^*[J]. 临床输血与检验, 2024, 26(5): 715-720.

PU Youwei, HU Xue, LUO Jinlian, YU Zebo. Research Progress in Treatment of Aplastic Anemia with Traditional Chinese Medicine[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 715-720.

参考文献

[1] LIU T,PAN Y,YE M H,et al.Experience of life quality from patients with aplastic Anemia:a descriptive qualitative study[J]. Orphanet J Rare Dis,2023, 18(1):393.
[2] 中华医学会血液学分会红细胞疾病(贫血)学组. 再生障碍性贫血诊断与治疗中国指南(2022年版)[J]. 中华血液学杂志,2022,43:(11): 881-888.
[3] YOUNG N S.Aplastic Anemia[J]. N Engl J Med,2018, 379(17):1643-1656.
[4] YOUNG N S.Current concepts in the pathophysiology and treatment of aplastic Anemia[J]. Hematology Am Soc Hematol Educ Program,2013,2013(1):76-81.
[5] URBANOWICZ I,NAHACZEWSKA W,CELUCH B.Narrative review of aplastic Anemia-the importance of supportive treatment[J]. Ann Palliat Med,2021, 10(1):694-699.
[6] 仇如意,叶宝东,侯佳慧,等.“补肾活血”法治疗慢性再生障碍性贫血患者输血相关性铁负荷过载的效果分析[J]. 中国输血杂志,2021,34(7):720-724.
[7] ZHENG B R,SHEN J P,ZHUANG H F,et al.Treatment of severe aplastic Anemia by immunosuppressor anti-lymphocyte globulin/anti-Thymus globulin as the chief medicine in combination with Chinese drugs[J]. Chin J Integr Med,2009,15(2):145-148.
[8] 赵瑞,杨丹,靳颖颖,等. 中西医结合治疗慢性再生障碍性贫血临床观察[J]. 实用中医药杂志,2021,37(6):953-955.
[9] 何丹,万丹,舒骏,等. 四物汤物质基础、药理作用及临床应用研究进展[J]. 中药药理与临床,2020,36(6):221-229.
[10] 苑军伟,吴静. 慢性再生障碍性贫血应用四物汤和常规西药治疗的研究[J]. 实用中西医结合临床,2020,20(3):70-71.
[11] 杨旭,杨讯,许词,等. 参芪四物汤治疗慢性再生障碍性贫血临床研究[J]. 新中医,2021,53(3):25-27.
[12] 代喜平,李琤,胡永珍,等.参芪四物汤结合分期辨证治疗慢性再生障碍性贫血30例[C]//中华中医药学会.中华中医药学会第二届岐黄论坛——血液病中医药防治分论坛论文集.广东省中医院血液科;2014:4.
[13] 陈艳红,李达,胡永珍,等. 参芪四物汤减少重度贫血患者输血的临床研究[J]. 中国输血杂志,2010,23(3):235-237.
[14] 马艳春,胡建辉,段莹,等. 当归补血汤研究进展[J]. 辽宁中医药大学学报,2023,25(2):10-13.
[15] 陆浩,夏明清,王辉,等. 当归补血汤联合左旋卡尼汀治疗肾性贫血的临床观察[J]. 世界中医药,2022,17(1):108-111.
[16] 谢东杰,王爱迪,刘宝山. 当归补血汤在血液疾病中作用机制的研究进展[J]. 中华中医药杂志,2018,33(6):2488-2490.
[17] 陈维达,徐龙晋,张静,等. 当归补血汤对再障小鼠骨髓造血及线粒体自噬的实验研究[J]. 中药药理与临床,2019, 35(1):14-18.
[18] 黎承平,杨弘,李维佳,等. 当归补血汤辅助治疗慢性再生障碍性贫血疗效观察[J]. 中国中医急症,2008,17(11): 1525.
[19] 李荣,孙伟正. 孙伟正教授治疗慢性再生障碍性贫血经验[J]. 中医药信息,2008,25(2):42-43.
[20] 周永明. 中西医结合治疗再生障碍性贫血的历史、现状与研究对策[C]//中国中西医结合学会血液学专业委员会.全国中西医结合血液学学术会议论文汇编.上海中医药大学附属岳阳中西医结合医院;,2010:5.
[21] 周郁鸿. 中医药治疗慢性再生障碍性贫血研究述评[J]. 北京中医药大学学报,2023,46(10):1461-1466.
[22] 于孙婉琪,谷梦宇,史文萱,等. 孙伟正教授从肾论治非重型再生障碍性贫血经验撷英[J]. 中医药信息,2022,39(3): 25-28.
[23] 吴迪炯,周郁鸿. 周郁鸿治疗慢性再生障碍性贫血经验[J]. 中医杂志,2013,54(4):338-340.
[24] 季建敏,章亚成,沈群,等. 中药复方“血复生” 治疗慢性再生障碍性贫血作用机制的研究[J]. 中国生化药物杂志, 2010,30(3):205-207.
[25] 李晓惠,章亚成,陈建一,等. “血复生汤” 为主治疗再生障碍性贫血118例的临床研究[J]. 江苏中医药,2002, 34(12):10-11.
[26] 沈慧芬,周郁鸿,沈一平. 周郁鸿教授自拟祛痰补肾汤治疗慢性再生障碍性贫血经验[J]. 浙江中医药大学学报, 2012,36(12):1264-1265.
[27] 符陆帅,魏克民. 魏克民教授治疗再生障碍性贫血经验撷菁[J]. 浙江中医药大学学报,2014,38(7):848-850.
[28] GALE R P,HINTERBERGER W,YOUNG N S,et al.What causes aplastic anaemia?[J]. Leukemia,2023,37(6): 1191-1193.
[29] REBER L,DA SILVA C A,FROSSARD N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases[J]. Eur J Pharmacol,2006,533(1/2/3):327-340.
[30] SHAN H J,JIANG K,ZHAO M Z,et al.SCF/c-Kit-activated signaling and angiogenesis require Gαi1 and Gαi3[J]. Int J Biol Sci,2023,19(6):1910-1924.
[31] 刘宝山,顾民华,范国平,等. 补肾化痰活血中药对再生障碍性贫血小鼠骨髓CD₃₄+和细胞因子表达的影响[J]. 辽宁中医杂志,2009,36(5):705-707.
[32] 刘涓,张弛,吴爱明,等. 补肾生血解毒方对再生障碍性贫血小鼠造血干细胞增殖的影响[J]. 北京中医药大学学报, 2013,36(8):538-541.
[33] 董玢,刘涓,娄利霞,等. 补肾生血解毒方对再生障碍性贫血小鼠红细胞生成相关细胞因子表达的影响[J]. 北京中医药大学学报,2014,37(6):397-400.
[34] 袁嘉婧,张静,陈泽涛. 当归补血汤对再障小鼠骨髓单个核细胞线粒体膜电位与自噬相关蛋白的作用研究[J]. 中药药理与临床,2020,36(3):53-56.
[35] MACIEJEWSKI J P,SELLERI C,SATO T,et al.Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia[J]. Br J Haematol,1995,91(1):245-252.
[36] Vibhuti,TRIPATHY N K,NITYANAND S. Massive apoptosis of bone marrow cells in aplastic anaemia[J]. Br J Haematol,2002,117(4):993-994.
[37] ZHANG L,NI R F,LI J N,et al.Dioscin regulating bone marrow apoptosis in aplastic Anemia[J]. Drug Des Devel Ther,2022,16:3041-3053.
[38] BAKHTIYARI M,LIAGHAT M,AZIZIYAN F,et al.The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression:immune checkpoints,metabolic checkpoints,and signaling pathways[J]. Cell Commun Signal,2023,21(1):252.
[39] PARK M,PARK C J,CHO Y W,et al.Alterations in the bone marrow microenvironment may elicit defective hematopoiesis:a comparison of aplastic Anemia,chronic myeloid leukemia,and normal bone marrow[J]. Exp Hematol,2017,45:56-63.
[40] TRIPATHY N K,SINGH S P,NITYANAND S.Enhanced adipogenicity of bone marrow mesenchymal stem cells in aplastic Anemia[J]. Stem Cells Int,2014,2014:276862.
[41] ZHANG X N,LIU L L,WANG J,et al.Emodin suppresses adipogenesis of bone marrow derived mesenchymal stem cells from aplastic Anemia via increasing TRIB3 expression[J]. Tissue Cell,2024,86:102287.
[42] DENG S,ZENG Y Q,XIANG J J,et al.Icariin protects bone marrow mesenchymal stem cells in aplastic Anemia by targeting MAPK pathway[J]. Mol Biol Rep, 2022,49(9):8317-8324.
[43] SOMASUNDARAM V,TEVATIA M S,PUROHIT A,et al.Evaluation of bone marrow microvessel density in patients with aplastic Anemia[J]. Indian J Hematol Blood Transfus,2017,33(2):169-174.
[44] GUPTA P,KHURANA N,SINGH T,et al.Bone marrow angiogenesis in aplastic Anemia—a study of CD 34 and VEGF expression in bone marrow biopsies[J]. Hematology,2009,14(1):16-21.
[45] 程丽芳. 愈障再生汤联合雄激素治疗慢性再生障碍性贫血疗效及对骨髓MVD、VEGF及FGF-1的影响[J]. 现代中西医结合杂志,2018,27(6):618-620.
[46] 邵克武,谢函君,刘登峰,等. 黄地再生丸对再生障碍性贫血小鼠模型的影响及其机制探讨[J]. 湖北中医药大学学报,2022,24(4):15-19.
[47] LI Y M,YU J F,WANG F,et al.MiR-150-5p regulate T cell activation in severe aplastic Anemia by targeting Bach2[J]. Cell Tissue Res,2021,384(2):423-434.
[48] SCHEINBERG P.Progress in medical therapy in aplastic Anemia:why it took so long?[J]. Int J Hematol,2024,119(3):248-254.
[49] ZHU C Y,LIAN Y,WANG C C,et al.Single-cell transcriptomics dissects hematopoietic cell destruction and T-cell engagement in aplastic Anemia[J]. Blood, 2021,138(1):23-33.
[50] SLOAND E,KIM S,MACIEJEWSKI J P,et al.Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic Anemia[J]. Blood,2002,100(4):1185-1191.
[51] WANG X A,LI J P,WU K H,et al.Mesenchymal stem cells in acquired aplastic Anemia:the spectrum from basic to clinical utility[J]. Int J Mol Sci,2023, 24(5):4464.
[52] KORDASTI S,MARSH J,AL-KHAN S,et al.Functional characterization of CD4+ T cells in aplastic Anemia[J]. Blood,2012,119(9):2033-2043.
[53] 魏丽萍. 加味当归补血汤治疗慢性再生障碍性贫血的临床研究[D].浙江中医药大学,2014.
[54] ZHOU J W,LI X,DENG P Y,et al.Chinese herbal formula,modified Danggui Buxue Tang,attenuates apoptosis of hematopoietic stem cells in immune-mediated aplastic Anemia mouse model[J]. J Immunol Res,2017,2017:9786972.
[55] 褚金龙,邢桂芝,沈春瑾,等. 三七总皂苷对再生障碍性贫血小鼠T淋巴细胞亚群的影响及其促造血作用[J]. 吉林大学学报(医学版),2019,45(4):807-812.
[56] ZHAO Y N,SUN X H,YU X L,et al.Saponins from Panax notoginseng leaves improve the symptoms of aplastic Anemia and aberrant immunity in mice[J]. Biomedecine Pharmacother,2018,102:959-965.
[57] SCHLÖDER J,SHAHNEH F,SCHNEIDER F J,et al. Boosting regulatory T cell function for the treatment of autoimmune diseases-That's only half the battle![J]. Front Immunol,2022,13:973813.
[58] SOLOMOU E E,REZVANI K,MIELKE S,et al.Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic Anemia[J]. Blood,2007,110(5):1603-1606.
[59] PUTRA W E,RIFA’I M. Assessing the immunomodulatory activity of ethanol extract of Sambucus javanica berries and leaves in chloramphenicol- induced aplastic Anemia mouse model[J]. Trop Life Sci Res,2020,31(2):175-185.
[60] FAN L W,NI R F,WANG H J,et al.Dioscin alleviates aplastic Anemia through regulatory T cells promotion[J]. Hematology,2024,29(1):2326389.
[61] 王旭丽, 林赠华, 刘红,等. 鹿龙再生汤对重型再生障碍性贫血小鼠CD4+CD25+调节性T细胞内Foxp3表达的影响. 中华血液学杂志, 2015, 36(08):689-691.
[62] 唐加龙,周莉,孙祖越,等. 网络药理学在中医药治疗自身免疫性疾病中的应用[J]. 中国药理学通报,2021,37(3): 323-327.
[63] 李秀云,章新友,吴地尧,等. 中药复方网络药理学研究的文献分析[J]. 中国药房,2021,32(2):182-189.
[64] YE M,LIU G X,YANG Y J,et al.Network pharmacology and experimental verification of the potential mechanism of Er-Xian decoction in aplastic Anemia[J]. Sci Rep, 2023,13(1):17385.
[65] 于大海,吕浩,赵丽珠. 基于网络药理学和分子对接法探索人参治疗再生障碍性贫血的分子机制[J]. 世界科学技术-中医药现代化,2022,24(2):749-761.
[66] 赵炳聪,李亚鸿,解红霞. 网络药理学在中药复方作用机制研究中的应用[J]. 中国中医药信息杂志,2020,27(3): 133-136.

中医药治疗再生障碍性贫血的研究进展^*

Research Progress in Treatment of Aplastic Anemia with Traditional Chinese Medicine

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	严美玲, 朱培元. 基于网络药理学与分子对接探讨桃红四物汤对血小板活化的作用机制^*[J]. 临床输血与检验, 2024, 26(2): 213-222.
[2]	陈岩, 陈麟凤, 何欣, 王岩, 于文娟, 刘璇, 刘思琪. 结直肠癌贫血患者围手术期用血影响因素分析: 一项单中心2013—2020年数据[J]. 临床输血与检验, 2024, 26(1): 79-85.
[3]	陈珊, 刘景福, 李珍, 陈玉娟, 叶先仁. 食管癌围手术期患者输血预测模型的建立^*[J]. 临床输血与检验, 2023, 25(6): 743-748.
[4]	耿凌云, 李景琦. 儿科患者血液管理的挑战与思考[J]. 临床输血与检验, 2023, 25(4): 439-443.
[5]	郭天虹, 王雨涵, Claudia SC, 黄远帅. 基于研究证据的输血医学新进展[J]. 临床输血与检验, 2023, 25(4): 572-576.
[6]	黄蓉, 张宁洁, 郝珂, 郭天虹, 黄雪原, 谷兰, 傅云峰, 黄远帅, 王勇军, 陈秉宇, 周岚, 桂嵘. 从《AABB技术手册》（18版-20版）看国际输血技术新走向^*[J]. 临床输血与检验, 2023, 25(2): 170-179.
[7]	夏悦昕, 刘志远, 宋文倩, 邵林楠, 梁晓华, 周世航. 先天性纯红细胞再生障碍性贫血氧化应激相关差异表达基因的生物信息学分析[J]. 临床输血与检验, 2023, 25(1): 82-87.
[8]	中国输血协会临床输血学专业委员会. 非心脏外科围手术期患者血液管理专家共识（2022版）[J]. 临床输血与检验, 2022, 24(5): 545-553.
[9]	陈学军, 徐军, 尹明伟, 周超, 沈月芳. 英格兰临床和实验室输血五年计划：输血2024的要点及启示[J]. 临床输血与检验, 2022, 24(5): 560-564.
[10]	王文静, 赵儒, 王琪, 陈利达, 陈文慧, 芦宏凯. 肺移植患者血液管理研究进展^*[J]. 临床输血与检验, 2021, 23(3): 404-408.
[11]	周文玲, 杨融辉, 金晶纯, 肇硕, 郝一文. 围手术期患者血液管理对手术用血量影响作用的分析[J]. 临床输血与检验, 2020, 22(5): 501-506.
[12]	张涛, 谭茜茜, 廖红梅, 刘不尽, 李浏卿, 芸邹, 晓萍, 欧阳熊妍, 毛伟, 兰炯采. 中医药在细胞凋亡中的作用以及对输血治疗的影响[J]. 临床输血与检验, 2019, 21(3): 248-251.
[13]	杨晓亮, 兰炯采, 胡雪, 王静, 李青, 余泽波. 中医药促进红细胞与血小板再生在输血医学中的应用与研究进展[J]. 临床输血与检验, 2019, 21(3): 252-255.
[14]	孙洁,陆韬宏,王春燕,刘渊,周蓉,孟妍. 患者血液管理在临床输血实践中的应用*[J]. 临床输血与检验, 2018, 20(4): 337-339.